In results of the phase III PRODIGE 24/CCTG PA.6 trial presented at the 2018 ASCO Annual Meeting, adjuvant mFOLFIRINOX significantly improved overall survival (OS) and progression-free survival (PFS) compared with gemcitabine in patients with metastatic pancreatic cancer. Read more . . .
Systemic chemotherapy with FOLFIRINOX should be the backbone of treatment for patients with locally advanced pancreatic cancer who have undergone surgical resection, said Matthew H.G. Katz, MD, FACS.